The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 28 April 2026•Updated 28 April 2026•

1 min read

Erasca Shares Plunge 50% Following Patient Death in Cancer Drug Trial

Key Facts

1Erasca shares fell over 35% before the bell following the disclosure of a patient death in an early-stage trial of an experimental cancer drug.

2Analysts stated the incident was unlikely to signal a broader safety issue despite the sharp decline in share price.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: Updated the story to include the release of preliminary Phase I data and technical details regarding the ERAS-0015 program.

Version 2about 1 month ago

What changed: Added information regarding Erasca's intent to legally contest allegations brought by Revolution Medicines.

Version 1about 1 month ago

What changed: Updated the stock price decline from 35% to 50% and included details regarding competition with Revolution Medicines.

Erasca shares plummeted 50% following a reported fatality in a clinical trial, intensifying investor scrutiny over its pipeline safety relative to Revolution Medicines' (RVMD) daraxonrasib. In a significant update, the company released preliminary Phase I data and technical details regarding its ERAS-0015 program to highlight its clinical differentiation. Erasca also confirmed it will legally contest allegations brought by RVMD, signaling an escalating legal conflict alongside its clinical challenges. While the market reaction remains severe, the release of specific technical slides aims to address concerns regarding the systemic safety of the drug candidate. Investors are now pivoting their focus toward the newly disclosed ERAS-0015 data and the progression of the legal dispute. This volatility underscores the high-stakes nature of the Biotech sector, where technical transparency and legal outcomes are critical to recovery.